Let’s start up with the current stock price of Avenue Therapeutics Inc. (ATXI), which is $0.22 to be very precise. The Stock rose vividly during the last session to $0.258 after opening rate of $0.258 while the lowest price it went was recorded $0.2101 before closing at $0.26.Recently in News on March 31, 2022, Abeona Therapeutics Announces Strategy Update and 2021 Financial Results. EB-101 pivotal phase 3 VIITAL™ study in RDEB achieves target enrollment; top-line data expected in third quarter of 2022; gained FDA alignment on CMC requirements for EB-101 including characterization and validation plans. You can read further details here
Avenue Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $1.2500 on 03/01/22, with the lowest value was $0.2000 for the same time period, recorded on 02/24/22.
Avenue Therapeutics Inc. (ATXI) full year performance was -87.05%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Avenue Therapeutics Inc. shares are logging -88.38% during the 52-week period from high price, and 7.50% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $0.20 and $1.85.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 823728 for the day, which was evidently lower, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Avenue Therapeutics Inc. (ATXI) recorded performance in the market was -76.32%, having the revenues showcasing -14.00% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 4.86M, as it employees total of 4 workers.
Market experts do have their say about Avenue Therapeutics Inc. (ATXI)
During the last month, 0 analysts gave the Avenue Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 0.2801, with a change in the price was noted -0.22. In a similar fashion, Avenue Therapeutics Inc. posted a movement of -50.52% for the period of last 100 days, recording 1,004,688 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ATXI is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.00.
Technical breakdown of Avenue Therapeutics Inc. (ATXI)
Raw Stochastic average of Avenue Therapeutics Inc. in the period of last 50 days is set at 3.52%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 3.52%. In the last 20 days, the company’s Stochastic %K was 11.95% and its Stochastic %D was recorded 20.42%.
Bearing in mind the latest performance of Avenue Therapeutics Inc., several moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -76.32%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -68.41%, alongside a downfall of -87.05% for the period of the last 12 months. The shares increased approximately by -6.56% in the 7-day charts and went up by -20.40% in the period of the last 30 days. Common stock shares were lifted by -14.00% during last recorded quarter.